Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR -- Ignore unavailable to you. Want to Upgrade?

To: Mr. L. Neufeldt who wrote (112)	2/1/2001 2:29:45 AM
From: Cal Gary	Read Replies (1) \| Respond to of 132

Hope this NR paves the way for your I'm led to believe there will be another analyst report coming out first week in February. DiagnoCure's ImmunoCyt is adopted by Laboratory Corp. DiagnoCure Inc CUR Shares issued 17,498,032 Jan 31 close $1.79 Wed 31 Jan 2001 News Release Mr. Pierre Desy reports DiagnoCure's bladder cancer test, ImmunoCyt, has been adopted by Laboratory Corporation of America Holdings. This event furthers DiagnoCure's penetration into the U.S. cancer diagnostics market. LabCorp is one of the largest independent commercial reference laboratories in the United States and a world leader in finding and adopting innovative diagnostics in the fields of cytology and oncology. The adoption of ImmunoCyt by LabCorp was made possible through the efforts of DiagnoCure's U.S. marketing and distribution partner, DAKO Corporation. "ImmunoCyt is increasingly finding acceptance and approval in the U.S. market and subsequently gaining market penetration. ImmunoCyt was only introduced to the United States in September of last year, and we are extremely pleased with the progress achieved thus far," said DiagnoCure president and chief executive, Pierre Desy. "Together with our partner, DAKO, we will continue to pursue similar arrangements with other leading U.S. reference laboratories." ImmunoCyt is used by pathologists in conjunction with classic urine cytology for the monitoring of disease recurrence. Results from clinical studies have shown that ImmunoCyt, when combined with cytology, improves the sensitivity rate of early-stage bladder cancer detection to more than 90 per cent. Danish private company DAKO is a leading global market leader in the marketing and distribution of diagnostic products for the pathology laboratory. As a pioneer in pharmacoDiagnostics -- therapy-linked diagnostics tools - DAKO's expanding product line includes cell and tissue cancer diagnostics, innovative detection systems, advanced instrumentation, flow cytometry and molecular systems. DAKO Corporation is the company's U.S. subsidiary, located in Carpinteria. LabCorp is a national U.S. clinical laboratory and a leader in the commercialization of innovative diagnostic technologies. With over 2,000 clinical tests ranging from simple blood analysis to sophisticated genomic tests, LabCorp possesses a comprehensive test menu for the evaluation, treatment and monitoring of bladder cancer uses diagnostic capabilities ranging from traditional methods such as cytology to leading-edge molecular genetic technologies. (c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com

To: Mr. L. Neufeldt who wrote (112)	2/3/2001 5:54:20 PM
From: Robert Dirks	Read Replies (1) \| Respond to of 132

Yep I got my core position in CUR now. Very happy with the prices this time round. Early last year I found out late about CUR and was buying above $3.50, which I later sold. Im ready and strapped in for the ride this year... The economy is confounding the specialists, but that just creates great trading oportunities. We will see volatility, but the market should be gravitating higher as the year progresses. Im confident that even with possible recession, Greenie's cuts and George W's Tax easing will power the US Markets. Check out GNX.M also. I expect some fireworks here. They are actually very similar to CUR in that its a Que BioTech co., relatively unknown, unpromoted, and CHEAP. Headed by Dr. Lebel, who seems to put her heart into that co...